Literature DB >> 11458539

Drug addictions. Molecular and cellular endpoints.

M J Kreek1.   

Abstract

Addiction to alcohol, tobacco, and illicit drugs of abuse continues to be one of the most significant medical, social, and economic problems facing our society. Since the mid-1960s, addictions have been recognized as diseases. We have hypothesized that three domains of factors contribute to the development and persistence of addictions: inherited or genetic differences in individual physiology, alterations in physiology induced by drugs or alcohol, and environmental or developmental factors. Neurochemical alterations in the brain caused by addictive drugs have a cellular and molecular basis and, in the setting of repeated self-exposure, which can lead to addiction, these changes may be persistent or even permanent. Such altered molecular, cellular, and neurophysiological "set points" in the brain, in turn, contribute to alterations in behavior with implications for the specific addictive diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458539

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  27 in total

Review 1.  Stress, dysregulation of drug reward pathways, and the transition to drug dependence.

Authors:  George Koob; Mary Jeanne Kreek
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

2.  A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.

Authors:  Kassi Psifogeorgou; Kassi Psigfogeorgou; Dimitra Terzi; Maria Martha Papachatzaki; Artemis Varidaki; Deveroux Ferguson; Stephen J Gold; Venetia Zachariou
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

3.  Chronic, but not acute morphine treatment, up-regulates alpha-Ca2+/calmodulin dependent protein kinase II gene expression in rat brain.

Authors:  Yuejun Chen; Yan Jiang; Wen Yue; Yuqing Zhou; Lin Lu; Lan Ma
Journal:  Neurochem Res       Date:  2008-04-12       Impact factor: 3.996

Review 4.  HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.

Authors:  Kurt F Hauser; Nazira El-Hage; Anne Stiene-Martin; William F Maragos; Avindra Nath; Yuri Persidsky; David J Volsky; Pamela E Knapp
Journal:  J Neurochem       Date:  2006-12-01       Impact factor: 5.372

5.  Analgesic tolerance to morphine is regulated by PPARγ.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Serena Stopponi; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Chronic morphine treatment switches the effect of dopamine on excitatory synaptic transmission from inhibition to excitation in pyramidal cells of the basolateral amygdala.

Authors:  Zicheng Li; Wenjie Luan; Yang Chen; Ming Chen; Yi Dong; Bin Lai; Lan Ma; Ping Zheng
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

7.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Effects of chronic expression of the HIV-induced protein, transactivator of transcription, on circadian activity rhythms in mice, with or without morphine.

Authors:  Marilyn J Duncan; Annadora J Bruce-Keller; Clayton Conner; Pamela E Knapp; Ruquiang Xu; Avindra Nath; Kurt F Hauser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-10       Impact factor: 3.619

9.  Layer selective presynaptic modulation of excitatory inputs to hippocampal cornu Ammon 1 by mu-opioid receptor activation.

Authors:  A R McQuiston
Journal:  Neuroscience       Date:  2007-10-11       Impact factor: 3.590

10.  Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior.

Authors:  Diana Simmons; David W Self
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.